Page last updated: 2024-10-31

entinostat and Cryptogenic Fibrosing Alveolitis

entinostat has been researched along with Cryptogenic Fibrosing Alveolitis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lu, W1
Yao, X1
Ouyang, P1
Dong, N1
Wu, D1
Jiang, X1
Wu, Z1
Zhang, C1
Xu, Z1
Tang, Y1
Zou, S1
Liu, M1
Li, J1
Zeng, M1
Lin, P1
Cheng, F1
Huang, J1
Kamio, K1
Azuma, A1
Usuki, J1
Matsuda, K1
Inomata, M1
Nishijima, N1
Itakura, S1
Hayashi, H1
Kashiwada, T1
Kokuho, N1
Atsumi, K1
Yamaguchi, T1
Fujita, K1
Saito, Y1
Abe, S1
Kubota, K1
Gemma, A1

Other Studies

2 other studies available for entinostat and Cryptogenic Fibrosing Alveolitis

ArticleYear
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
    Journal of medicinal chemistry, 2017, 03-09, Volume: 60, Issue:5

    Topics: Acute Lung Injury; Animals; Epoxide Hydrolases; Female; Histone Deacetylase Inhibitors; Idiopathic P

2017
XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts.
    Pulmonary pharmacology & therapeutics, 2017, Volume: 44

    Topics: Benzamides; Cells, Cultured; Extracellular Matrix; Fibroblasts; Gene Silencing; Histone Deacetylase

2017